Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Copanlisib in Combination with Degarelix in Treating High-Risk Localized Prostate Cancer prior to Radical Prostatectomy, The CHARIOT Trial

Trial Status: temporarily closed to accrual

This phase 1b/2 trial studies the side effects and best dose of copanlisib in combination with degarelix, and how well the combination works in treating patients with high-risk prostate cancer that has not spread to other parts of the body (localized) prior to surgery to remove the entire prostate (radical prostatectomy). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Degarelix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the body to stop making testosterone, which prostate cancer needs to grow. Giving copanlisib and degarelix prior to radical prostatectomy may work better than degarelix alone prior to radical prostatectomy in treating high-risk localized prostate cancer.